

Master Framework and Pragmatic Clinical Trial for Relapse or Refractory Acute Myeloid Leukemia (IMPACT- AML)

Dr Petros Kountouris
The Cyprus Institute of Neurology and Genetics
17 February 2023

The Cyprus Institute of Neurology and Genetics (CING)



- Established in 1990 as a **private, bi-communal, non-profit research, academic and medical** organization.
- Postgraduate School since 2012.
- Center of excellence** for high quality **services**, innovative **research** and postgraduate **education**.



Offer specialized services in the fields of neurology, genetics & biomedical sciences.



Innovative and translational research is carried out with main benefits to the society.



The Cyprus Institute of Neurology & Genetics has developed the facilities and an atmosphere ...



THE CYPRUS INSTITUTE OF
NEUROLOGY & GENETICS

Molecular Genetics Thalassemia Department

- The central national and regional reference laboratory for molecular diagnosis of thalassaemia
- Research Directions:
 - a) Prenatal molecular, pre-implantation genetic and non-invasive prenatal diagnosis,
 - b) Genotype-phenotype correlation studies in thalassaemia,
 - c) Advancing and customizing gene therapy for thalassaemia and other blood diseases,
 - d) Bioinformatics and medical informatics

Research activities

The ITHANET Portal – a knowledgebase for haemoglobinopathies

International Hemoglobinopathy Research Network (INHERENT)

ClinGen Hemoglobinopathy Variant Curation Expert Panel (VCEP)

GenoMed4All (H2020)

African Research and Innovative Initiative for Sickle Cell Disease (ARISE)

ERN-EuroBloodNet => Development of patient registries (RADeep and ENROL)



EuroBloodNet



RADeep



ENROL



ithanet



INHERENT
International Hemoglobinopathy Research Network



GENOMED4ALL



ClinGen
Clinical Genome Resource



ARISE
African Research And Innovative
Initiative For Sickle Cell Education

IMPACT-AML

- Call: HORIZON-MISS-2022-CANCER-01-03 — Pragmatic clinical trials to optimize treatments for patients with refractory cancers
- Duration: 60 months (May 2023 – Apr 2028)
- Funding: ~ 6M euros

IMPACT-AML

- Coordinator: IRCSS Istituto Romagnolo per lo Studio e la Cura dei Tumori “Dino Amadori” (IRST)
- 17 partners from 7 EU countries
 - Demonstrated capacity to attract additional participants through the participation of large European networks




IMPACT-AML

Main objectives

- to create an inclusive **master framework for relapsed or refractory acute myeloid leukemia** (STREAM) to include patients with R/R AML across Europe proficiently acquire an unselected population for clinical trials and monitor outcomes including neglected cohorts
- To conduct a **prospective randomized pragmatic clinical trial** (RPCT) that will compare the classical “high intensity” rescue chemotherapy with biology-driven, “low intensity” rescue to obtain “real world” data on the benefit of one of the two different strategies in term of survival also considering patients and caregivers preferences, patient-reported outcomes (PRO), accessibility, affordability, and social cost.

IMPACT-AML



Tips

- Networking – take initiatives to expand your network
- Find your niche
- Be an active collaborator – contribute to proposal preparation and project activities
- Keep trying

Thank you for your attention